Cargando…

Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension

Liver cirrhosis is a frequent condition with high impact on patients’ life expectancy and health care systems. Cirrhotic portal hypertension (PH) gradually develops with deteriorating liver function and can lead to life-threatening complications. Other than an increase in intrahepatic flow resistanc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kreisel, Wolfgang, Schaffner, Denise, Lazaro, Adhara, Trebicka, Jonel, Merfort, Irmgard, Schmitt-Graeff, Annette, Deibert, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503357/ https://www.ncbi.nlm.nih.gov/pubmed/32872119 http://dx.doi.org/10.3390/ijms21176223

Ejemplares similares

Cyclic GMP in Liver Cirrhosis—Role in Pathophysiology of Portal Hypertension and Therapeutic Implications
por: Kreisel, Wolfgang, et al.
Publicado: (2021)

Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension
por: Schaffner, Denise, et al.
Publicado: (2018)

Beneficial long term effect of a phosphodiesterase-5-inhibitor in cirrhotic portal hypertension: A case report with 8 years follow-up
por: Deibert, Peter, et al.
Publicado: (2018)

Close Relationship between Systemic Arterial and Portal Venous Pressure in an Animal Model with Healthy Liver
por: Lazaro, Adhara, et al.
Publicado: (2023)

Phosphodiesterase 5 inhibitors lower both portal and pulmonary pressure in portopulmonary hypertension: a case report
por: Bremer, Hinrich C, et al.
Publicado: (2007)

Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension
por: Uschner, Frank E., et al.
Publicado: (2015)

Novel Rat Model of Repetitive Portal Venous Embolization Mimicking Human Non-Cirrhotic Idiopathic Portal Hypertension
por: Klein, Sabine, et al.
Publicado: (2016)

Managing portal hypertension in patients with liver cirrhosis
por: Sauerbruch, Tilman, et al.
Publicado: (2018)

Future therapy of portal hypertension in liver cirrhosis – a guess
por: Sauerbruch, Tilman, et al.
Publicado: (2014)

Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy
por: Iwakiri, Yasuko, et al.
Publicado: (2021)

Esophageal lichen planus: Current knowledge, challenges and future perspectives
por: Decker, Annegrit, et al.
Publicado: (2022)

Comprehensive lifestyle intervention vs soy protein-based meal regimen in non-alcoholic steatohepatitis
por: Deibert, Peter, et al.
Publicado: (2019)

The Role of miRNA-34a as a Prognostic Biomarker for Cirrhotic Patients with Portal Hypertension Receiving TIPS
por: Jansen, Christian, et al.
Publicado: (2014)

Mas‐related G protein‐coupled receptor type D antagonism improves portal hypertension in cirrhotic rats
por: Gunarathne, Lakmie S., et al.
Publicado: (2022)

Cirrhotic portal hypertension: From pathophysiology to novel therapeutics
por: Gunarathne, Lakmie S, et al.
Publicado: (2020)

Editorial: Portal Hypertension in Cirrhosis: From Pathogenesis to Novel Treatments
por: Herath, Chandana B., et al.
Publicado: (2022)

Phosphodiesterase-5 inhibitors have distinct effects on the hemodynamics of the liver
por: Halverscheid, Leonie, et al.
Publicado: (2009)

Protein-losing pseudomembranous colitis with cap polyposis-like features
por: Kreisel, Wolfgang, et al.
Publicado: (2017)

Etiology and Complications of Portal Vein Thrombosis
por: Trebicka, Jonel, et al.
Publicado: (2014)

Gastrointestinal Bleeding in Cirrhotic Patients with Portal Hypertension
por: Biecker, Erwin
Publicado: (2013)

Causes and Management of Non-cirrhotic Portal Hypertension
por: Gioia, Stefania, et al.
Publicado: (2020)

Wall shear stress in portal vein of cirrhotic patients with portal hypertension
por: Wei, Wei, et al.
Publicado: (2017)

The Impact of Partial Splenic Embolization on Portal Hypertensive Gastropathy in Cirrhotic Patients with Portal Hypertension
por: Saeki, Michio, et al.
Publicado: (2023)

Cardiac dysfunction in cirrhotic portal hypertension with or without ascites
por: Dadhich, Sunil, et al.
Publicado: (2014)

Idiopathic non-cirrhotic portal hypertension: a review
por: Schouten, Jeoffrey NL, et al.
Publicado: (2015)

The beneficial effects of curcumin in cirrhotic rats with portal hypertension
por: Hsu, Shao-Jung, et al.
Publicado: (2017)

Research progress on signaling pathways in cirrhotic portal hypertension
por: Xu, Wen, et al.
Publicado: (2018)

Non-cirrhotic portal hypertension in an ankylosing spondylitis patient
por: Park, Sukki, et al.
Publicado: (2018)

Non-Cirrhotic Portal Hypertension in Systemic Lupus Erythematosus
por: Suárez-Díaz, Silvia, et al.
Publicado: (2023)

Antibody and complement levels in patients with hypersplenism associated with cirrhotic portal hypertension and therapeutic principles
por: Zhang, Kun, et al.
Publicado: (2022)

The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats
por: Schwabl, Philipp, et al.
Publicado: (2018)

Splenic arteriovenous fistula leading to non-cirrhotic portal hypertension: a case report: Splenic arteriovenous fistula leading to non-cirrhotic portal hypertension
por: Abou Yassine, Ahmad, et al.
Publicado: (2023)

Nitro-oxidative stress, VEGF and MMP-9 in patients with cirrhotic and non-cirrhotic portal hypertension
por: MUTI, LEON ADRIAN, et al.
Publicado: (2015)

Pathological abnormalities in splenic vasculature in non-cirrhotic portal hypertension: Its relevance in the management of portal hypertension
por: Gupta, Shahana, et al.
Publicado: (2020)

Portal vein thrombosis in patients with cirrhosis
por: von Köckritz, Leona, et al.
Publicado: (2017)

Non-cirrhotic portal vein thrombosis – therapeutic challenge
por: Sarquis, Lucas Mansano, et al.
Publicado: (2022)

Chronic Myeloid Leukemia Presenting as Non-cirrhotic Portal Hypertension
por: Gemnani, Rinkle R, et al.
Publicado: (2023)

Rho-kinase inhibitor coupled to peptide-modified albumin carrier reduces portal pressure and increases renal perfusion in cirrhotic rats
por: Klein, Sabine, et al.
Publicado: (2019)

Cirrhotic Endothelial Progenitor Cells Enhance Liver Angiogenesis and Fibrosis and Aggravate Portal Hypertension in Bile Duct-Ligated Cirrhotic Rats
por: Tripathi, Dinesh Mani, et al.
Publicado: (2020)

Case Report: Assessing COVID-19 Transmission in Professional Volleyball in Germany, September to December 2020: An Epidemiological Study
por: Morath, Oliver, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1bthlqt8s2usj253f74s9d85k0